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Abstract
Background: Expression of the androgen receptor (AR) is associated with androgen-dependent proliferation arrest
and terminal differentiation of normal prostate epithelial cells. Additionally, activation of the AR is required for
survival of benign luminal epithelial cells and primary cancer cells, thus androgen deprivation therapy (ADT) leads
to apoptosis in both benign and cancerous tissue. Escape from ADT is known as castration-resistant prostate cancer
(CRPC). In the course of CRPC development the AR typically switches from being a cell-intrinsic inhibitor of normal
prostate epithelial cell proliferation to becoming an oncogene that is critical for prostate cancer cell proliferation. A
clearer understanding of the context dependent activation of the AR and its target genes is therefore desirable.
Methods: Immortalized human prostate basal epithelial EP156T cells and progeny cells that underwent epithelial to
mesenchymal transition (EMT), primary prostate epithelial cells (PrECs) and prostate cancer cell lines LNCaP, VCaP
and 22Rv1 were used to examine context dependent restriction and activation of the AR and classical target genes,
such as KLK3. Genome-wide gene expression analyses and single cell protein analyses were applied to study the
effect of different contexts.
Results: A variety of growth conditions were tested and found unable to activate AR expression and transcription
of classical androgen-dependent AR target genes, such as KLK3, in prostate epithelial cells with basal cell features or
in mesenchymal type prostate cells. The restriction of androgen- and AR-dependent transcription of classical target
genes in prostate basal epithelial cells was at the level of AR expression. Exogenous AR expression was sufficient for
androgen-dependent transcription of AR target genes in prostate basal epithelial cells, but did not exert a positive
feedback on endogenous AR expression. Treatment of basal prostate epithelial cells with inhibitors of epigenetic
gene silencing was not efficient in inducing androgen-dependent transcription of AR target genes, suggesting the
importance of missing cofactor(s).
Conclusions: Regulatory mechanisms of AR and androgen-dependent AR target gene transcription are
insufficiently understood and may be critical for prostate cancer initiation, progression and escape from standard
therapy. The present model is useful for the study of context dependent activation of the AR and its transcriptome.
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Background
Since the 1940s advanced prostate cancer has been
treated with surgical or chemical castration in order to
reduce systemic androgen levels [1]. The cumulative ex-
perience is that such androgen deprivation therapy
(ADT) leads to efficient regression of invasive prostate
cancer and to reduced levels of the serological marker
prostate-specific antigen (PSA). Unfortunately, ADT
seems not to increase long-term overall survival of pros-
tate cancer [2], and castration-resistant prostate cancer
(CRPC) in patients on ADT is typically diagnosed by ris-
ing serum PSA levels. Patients with CRPC have a poor
prognosis [3], and patients with metastases have shown
median overall survival of ≤19 months [4]. Androgens,
in particular dihydrotestosterone, are activating ligands
of the androgen receptor (AR) transcription factor.
Novel highly potent drugs that block either androgen
production or its stimulation of the AR have shown
effect in CRPC and are associated with an extended me-
dian survival of several months [1, 5]. Nonetheless,
CRPC remains incurable and progresses in spite of any
current therapy. The AR has been shown to be critical
to proliferation and survival of the bulk population of
prostate cancer cells both in early prostate cancer and in
CRPC, but different mechanisms are at play. In physio-
logical prostate homeostasis the prostate epithelium is
dependent upon a paracrine mechanism according to
which androgen stimulates the stromal AR to induce ex-
pression of diffusible growth factors such as FGF7,
FGF10, IGF1 and EGF which are essential for prostate
basal epithelial cell proliferation [6]. Epithelial basal cell
expression of the AR with androgen available leads to pro-
liferation arrest and luminal terminal cell differentiation.
During progression of prostate cancer the AR switches
from an epithelial anti-proliferative transcription factor to
an oncogene. This may occur in a stepwise fashion by still
incompletely understood molecular mechanisms. Several
possibly independent steps in CRPC cell generation
encompass the loss of ligand-bound AR-dependent inhib-
ition of proliferation, the oncogenic addiction to AR sig-
naling and the replacement of paracrine AR signaling by
autocrine growth factor signaling [7–9].
The molecular mechanisms that underlie AR tran-
scriptional induction in normal prostate epithelial
homeostasis and to which extent these mechanisms are
retained in putative prostate cancer stem cells (CSCs)
are not understood. One hypothesis that could explain
that prostate cancer invariably escapes from ADT and
androgen targeted therapy (ATT) would be the existence
of a subpopulation of prostate CSCs that are AR nega-
tive and therefore insensitive to androgen deprivation.
Evidence has been found to support the paradoxical pos-
sibility that ADT and ATT could lead to expansion of
the pool of prostate CSCs [3] hypothetically due to loss
of negative feedback by more differentiated cancer cells.
Additional consequences of ADT and ATT could be to
induce reprogramming plasticity of CSCs such as epithe-
lial to mesenchymal transition (EMT) or neuroendocrine
transdifferentiation [1, 5].
The understanding of essential molecular mechanisms
of putative prostate CSCs is hampered by the low num-
ber of these cells in patient materials. If those cells are
AR negative and AR non-responsive and give rise to AR
positive and AR-dependent cells it is possible that some
features of normal prostate cells are retained, although
with loss of abilities to terminal differentiation and
apoptosis induction. Better understanding of normal dif-
ferentiation is likely to offer new insights into tumor ini-
tiation and may help explain the functional significance
of common genetic alterations seen in prostate cancer
[10]. Utilizing a previously published model of stepwise
prostate carcinogenesis [11–15] and prostate cancer cell
lines we therefore undertook a further examination of
conditions for the restriction of AR and classical AR tar-
get gene expression in different cellular contexts.
Methods
Reagents, antibodies, cell culture and cell lines
Primary Prostate Epithelial Cells (PrECs; American Type
Culture Collection (ATCC); Cat# ATCC-PCS-440-010)
and prostate cancer cell lines LNCaP (ATCC-CRL-1740),
VCaP (ATCC-CRL-2876) and 22Rv1 cells (ATCC-CRL-
2505) were bought from LGC Standards GmbH (Wesel,
Germany). The prostate cell lines EP156T, EPT1, EPT2
and PrECs were grown in MCDB153 medium (Biological
Ind. Ltd., Israel) with 1 % for EP156T and PrECs, and 5 %
fetal calf serum (FCS) for EPT1 and EPT2 cells, and sup-
plemented with growth factors and antibiotics as described
elsewhere [13, 15]. EPT3 cells were grown in Ham’s F12
medium (Lonza, Basel, Switzerland, Cat# 3 MB147) with
5 % FCS. Cells with exogenous AR were grown in equiva-
lent medium but without androgens and with charcoal
stripped FCS. LNCaP and 22Rv1 cells were grown in
RPMI-1640 (Lonza, Cat# BW12-702 F) with 10 % FCS.
VCaP were grown in DMEM (Lonza, Cat# BE12-604 F)
with 10 % FCS. For experiments investigating the effect of
high calcium, cells were grown in standard MCDB-153
medium supplemented with 1 % FCS, 1 % FCS and
600 μM Ca(NO3)2, 10 % FCS or grown in RPMI-1640 with
10 % FCS. To study epigenetic restriction cells were grown
in standard medium with 10 μM 5-Aza-2′-deoxycytidine
(5-Aza-dC) (Sigma Aldrich, St. Louis, MO, USA, Cat#
A3656) for five days with addition of 250 nM trichostatin
A (TSA) (Sigma Aldrich, Cat# T1952) the last two days.
Medium was changed each day. DNA microsatellite
validation of progeny identity of EP156T, EPT1, EPT2,
EPT3-PT1 and EPT3-M1 cells has been published previ-
ously [15]. Matrigel-overlay cultures were performed with
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modifications based on Debnath J et al. [16] with a bed of
growth factor reduced (GFR) Matrigel (Cat# 356231, BD
Biosciences) and 2 % GFR Matrigel in the medium,
medium was changed every 3–4 days. Cells were grown in
a humidified atmosphere containing 5 % CO2 at 37 °C. Pri-
mary antibodies; AR (Cat# ab133273, ab9474), actin (Cat#
ab8226), GAPDH (Cat# ab181602) and PSA (Cat#
ab53774) were purchased from Abcam (Cambridge, UK).
Vectors, transfection and transduction
The pLenti6.3/V5-DEST-AR expression clone was gener-
ated by LR recombination reaction between the entry
clone pDONR-AR (Genecopoeia™, Rockville, MD, United
States, Cat# GC-E2325), and the destination vector
pLenti6.3/V5-DEST. Correct insertion of the AR gene was
verified by sequencing with CMV forward primer and
V5(C-term) reverse primer, according to the manufac-
turer’s protocol (Invitrogen, Life Technologies, Carlsbad,
CA, United States, Cat# V533-06).
The pLenti6.3/V5-DEST-AR and ViraPower™ Packaging
Mix were co-transfected in the 293FT producer cell line,
according to the manufacturer’s protocol (Invitrogen,
Cat# K370-20). EP156T and EPT3-PT1 cells were seeded
in six-well plates and infected with the viral supernatant.
After 48 h incubation the supernatant was removed and
cells were maintained in androgen-free MCDB medium
with 2 μg/ml blasticidine for the selection of stably trans-
duced EP156T-AR and EPT3-PT1-AR cells. Negative con-
trol cells were made for each cell type using the pLenti6.3/
V5-GW/lacZ control vector (Invitrogen, Cat# K370-20).
Indirect immunofluorescence assay (IF) and Western
blotting (Wb)
For IF, cells were grown on 12 mm glass coverslips
(Assistent, Sondheim v. d. Rhön Germany, Cat. # 1014/
12/1001) in 24 well plates, then washed with PBS, fixed
(4 % fresh formaldehyde in PBS for 20 min. at room
temperature), permeabilized (0.5 % Triton X-100 for
10 min.), blocked (100 mM glycin for 10 min) and
stored (in PBS at 4 °C) with PBS washes between each
step. Following blocking with 0.5 % BSA/PBS for
15 min. primary antibodies were added at room
temperature for 1 hour at indicated dilutions in 0.5 %
BSA/PBS. The FITC-labelled secondary anti-rabbit or
mouse IgG (Southern Biotech, Cat# 4050–02, 1030–02)
was added for 30 minutes at room temperature in 0.5 %
BSA/PBS. Coverslips were mounted in Prolong Gold
with DAPI (Molecular Probes, Life Technologies, Cat#
P-36931) on glass slides and analyzed using Leica DM
IRBE fluorescence microscopy.
For Wb analysis cells were lysed in RIPA-buffer with
1:100 Protease Inhibitor Cocktail Set I (Calbiochem,
Cat# 535142). Protein concentrations were measured
using the Pierce BCA Protein Assay Kit (ThermoFisher
Scientific, Waltham, MA, Cat# 23225), and 5 μg protein
lysates were separated by SDS electrophoresis in
NuPAGE® 10 % Bis-Tris Gels (LifeTechnologies, Carlsbad,
CA, United States, Cat# NP0303BOX) followed by blot-
ting to PVDF membranes (GE Healthcare Life Sciences,
Cat# RPN1416F) using Pierce 1-Step Transfer Buffer
(ThermoFisher, USA, Cat# 84731) and Pierce G2 Fast
Blotter (ThermoFisher). Membranes were blocked for one
hour in PBS 0.1 % Tween and 5 % Skim milk powder
(Sigma Aldrich, St. Louis, MO, USA, Cat# 70166). Primary
antibodies were incubated for 1 hour in blocking buffer at
RT, and HRP-labelled secondary antibodies (GE Health-
care, Little Chalfont, UK, Cat# NA931V, NA934V), were
incubated as the primary antibodies 1/10000. Pierce ECL
Western Blotting Substrate (ThermoFisher, Cat# 23106)
or SuperSignal West Femto Maximum Sensitity Substrate
(ThermoFisher, Cat# 34096) was used for detection with
Chemidoc XRS using Quantity One 4.6.5 (Bio-Rad).
Molecular weight marker used was MagicMark XP (Life
Technologies, Cat# LC5602).
PSA quantification assay
Cell culture supernatants were centrifuged in an Eppendorf
centrifuge at 14 000 x g for 2 minutes at room temperature,
and 0.5 ml of the supernatants were analyzed using the
Elecsys total PSA immunoassay (#04641655 190) in a
Cobas analyzer (Roche, Basel, Switzerland) according to the
kit manual and according to the accredited routines of the
Laboratory of Clinical Biochemistry (LKB) Haukeland
University Hospital. The lower detection limit is 0.003 ng/
ml total PSA. Values above 100 ng/ml are considered above
the measuring range.
RNA purification, TaqMan real-time RT-qPCR and Agilent
microarrays
Total RNA was extracted using the miRNeasy kit from
Qiagen (Qiagen, Venlo, Netherlands, Cat# 217004). The
total RNA was DNase treated, ss-cDNA was synthesized
and the RT-qPCR was run and analyzed as previously de-
scribed [17], using pre-designed Taqman probes (Life
Technologies) with the following Assay ID numbers:
ACTB (Hs99999903_m1), AR (Hs00171172_m1), KLK3
(Hs02576345_m1), NKX3-1 (Hs00171834_m1), TMPRSS2
(Hs00237175_m1). The Agilent Human Whole Genome
(4x44 k) Oligo Microarray with Sure Print Technology
(Agilent Technologies, Palo Alto, CA, US, Design #
G4112-60520 G4845-60510), was used to analyze samples
in the present study. Total RNA purification, cDNA label-
ing, hybridization and normalization have been described
previously [17, 18]. Following normalization, significance
analysis of microarray (SAM) of the J-Express program
package (http://www.molmine.com) [19] was used for
identification of differentially expressed genes. Only genes
that changed at least 2.0 fold with FDR below 10 % were
Olsen et al. BMC Cancer  (2016) 16:377 Page 3 of 15
considered as differentially expressed genes in cell lines.
ArrayExpress ID for the EP156T and EPT1 cells is (ID: E-
TABM-949), EPT2 and EPT3 cells is (ID: E-MTAB-1521)
[15] and for the EP156T, EP156T-LacZ, EP156T-AR,
LNCaP, VCaP and 22Rv1 cell lines (ID: E-MTAB-3715).
RNA sequencing (RNA-seq)
Total RNAs were included for RNA-seq if RIN (RNA In-
tegrity Number) was above 9 and total RNA was at least
500 ng according to the Agilent 2100 Bioanalyzer™. Illu-
mina HiSeq™ 2000 (Illumina) RNA-Seq was performed
according to manufacturer’s instructions and according
to StarSeq™ (Mainz, Germany) protocols. Prior to cDNA
synthesis rRNA depletion of total RNA was done. The
Qubit™/Bioanalyzer™ instruments were used for concen-
tration and quality control and fragmentation and sizing
was achieved using the CovarisTMS2 (Brighton, UK) kits
and instrumentation according to instructions. cDNAs
were tagged with barcoded adapters for multiplexing.
Paired-end sequencing with read length 150 base pairs
and 100 million reads per sample were chosen for raw
sequence data acquisition. Raw data were formatted in
BAM files and mapped to the December 2013 build of
the UCSC Human genome browser. The following mod-
ule versions were used in the TopHat and Cufflinks ana-
lyses for alignment and to estimate expression levels:
TopHat2 v2.0.7, Bowtie 0.12.9, Cufflinks 2.1.1, Isaac
Variant Caller 2.0.5, Picard tools 1.72. RNA-seq data is
available at Gene Expression Omnibus (ID: GSE71797).
Statistical analysis
Results from real-time RT-qPCR were analyzed using
the RQ Manager v1.2 software and DataAssist v3.01
(both Applied Biosystems, Foster City, CA, USA). Error
bars show 95 % confidence intervals. 95 % confidence in-
tervals were analyzed for secreted PSA values using
Microsoft Excel 2011 (Redmond, WA, USA).
Results
Restriction of AR and classical AR target gene expression
in immortalized prostate basal epithelial cells
The restricted expression of the androgen receptor and
classical AR target genes were initially validated in pros-
tate epithelial cells with basal cell features. The EP156T
cells are hTERT immortalized prostate basal epithelial
cells [11, 13, 18, 20] that can be passaged indefinitely as
transit amplifying cells in subconfluent monolayer
cultures. EP156T cells were examined at different pas-
sages with different concentrations of androgen in the
growth medium. AR mRNA could not be detected in ei-
ther of these conditions using Agilent oligonucleotide
microarray analyses (Fig.1a), and this was supported by
RNA-seq (Table 1) and validated by TaqMan reverse
transcription quantitative PCR (RT-qPCR) assays
(Fig. 1b). The transcription of a core set of classical AR
target genes in prostate epithelial cells was focused on
and consisted of KLK3, TMPRSS2, KLK2, NKX3-1 and
FKBP5. Of these, KLK3 and KLK2 mRNAs were non-
detectable using highly sensitive assays (Fig. 1a/b/c and
Table 1) and none of these target genes could be in-
duced to higher expression following addition of the
synthetic androgen R1881 at different concentrations to
the growth media (Fig. 1a/b/c). As expected no AR pro-
tein was detectable in Western blots (Fig. 1d). In order
to test the robustness of the repressed expression of the
AR and AR target genes, numerous growth factors, com-
bination of growth factors and growth conditions were
tested as exemplified in Additional file 1: Table S1. FGF7
has been shown to promote luminal differentiation [21].
EGF is used in the MCDB medium, but has been shown
to retard luminal differentiation, therefore removal of
EGF and addition of the MAPKK inhibitor PD98059 was
examined [22]. We also investigated if co-culture with
mesenchymal EPT1 cells or if growth in a three-
dimensional Matrigel-overlay culture could stimulate
differentiation of EP156T cells. A highly sensitive PSA
immunoassay was used to screen cell culture superna-
tants and this was negative at all conditions tested for
the EP156T cells in contrast to the very high PSA values
detected in growth medium of the LNCaP positive con-
trol cells (Additional file 1: Table S1).
Expression of the AR and AR target genes in primary
prostate cells and prostate cancer cell lines
Transcription of AR and AR target genes were then
tested in parallel controls in primary epithelial prostate
cells (PrECs) and the established prostate cancer cell
lines LNCaP, VCaP and 22Rv1. LNCaP cells are widely
used as an approximation to androgen sensitive cancer
and 22Rv1 cells are considered one model of AR positive
CRPC. PrECs reach senescence and die following a lim-
ited number of cell divisions. A low level of AR mRNA
was detectable in PrECs according to sensitive RT-qPCR
assays. But addition of androgen did not lead to in-
creased expression of AR target genes as exemplified for
the KLK3, NKX3-1 and TMPRSS2 mRNA (Fig. 1b/c). In
Western blots no AR was detectable in PrECs (Fig. 1d).
In contrast, striking AR target gene expression patterns
were induced by androgen in the 3 cancer cell lines
(Fig. 1a/d, Table 1). Addition of both 1 nM and 10 nM of
the synthetic androgen R1881 led to decreased AR mRNA
and protein in LNCaP cells in 48 hours as previously pub-
lished [23, 24] (Table 1 and Fig. 1d). The RNA-seq data
show that 1 nM R1881 for 24 hours decreased AR mRNA
levels in VCaP cells 2.8 fold and 10 nM R1881 for 48 hours
decreased AR mRNA levels in LNCaP cells 1.8 fold
(Table 1). This androgen-repressive effect on AR mRNA
was much less pronounced in the 22Rv1 cells. As shown
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in Table 1, androgen led to strong upregulation of the
classical AR target genes in spite of reduced absolute
levels of the AR, e.g. KLK3 was upregulated 22.8 fold in
LNCaP, 10.4 fold in VCaP and 2.3 fold in 22Rv1 cells
(Table 1).
Neither high calcium medium nor epigenetic modifiers
are sufficient to induce AR expression
Notch signaling is required for normal prostate epithelial
cell proliferation and differentiation [25]. EP156T cells are
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Fig. 1 Expression data of EP156T and PrEC cells. a Agilent microarray gene expression data for the indicated gene symbols are shown in the heatmap
according to supervised hierarchical cluster analysis (J-Express™ software) of different cell types with or without androgen R1881 in the growth medium.
EP156T and LNCaP cells were treated with 10 nM for 48 hours and 22Rv1 and VCaP cells with 1 nM R1881 for 24 hours. Red color indicates high
expression. b and c RT-qPCR comparing expression of AR, NKX3-1, TMPRSS2 and KLK3 between EP156T and PrECs. dWestern Blot of AR and PSA in PrEC
and EP156T cells compared to LNCaP cells with ± 1 nM R1881 stimulation for 48 hours. e RT-qPCR of AR and TP63 in EP156T cells after 6 days culture under
different calcium and FCS concentrations. N.D. = not detected. Error bars show 95 % confidence intervals. RQ = relative quantity
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signaling is constitutively activated while E-cadherin
(CDH1) signaling is inhibited [26]. It has previously been
published that changing to a high-calcium growth
medium leads to differentiation of EP156T cells [27].
EP156T cells were grown in MCDB medium supple-
mented with 600 μM calcium or RPMI-1640 + 10 % FCS,
also containing about 600 μM calcium. As AR expression
levels in EP156T are around the detection limit of RT-
qPCR, DNA input was increased 10-fold for AR assays.
We observed that calcium supplementation of the regular
MCDB growth medium resulted in negligible changes in
expression of AR and TP63 while growth in RPMI-1640
and 10 % FCS resulted in a 3-fold upregulation of AR
mRNA and >80 % reduction of the basal marker TP63.
Additionally, cells were grown in regular MCDB growth
medium supplemented with 10 % FCS, resulting in an
about 30 % decline in AR and TP63 mRNA (Fig. 1e), sug-
gesting that neither the calcium concentration nor the
high FCS can account for the differentiating effect in con-
trast to what has previously been suggested [27]. To cor-
roborate these findings, parallel experiments with PrECs
showed a decrease of TP63 expression in all conditions,
while AR expression was upregulated about 1.5 fold by
600 μM calcium and 10 % FCS and no change seen in
RPMI-1640 medium, adding further complexity to the
role of extracellular calcium in prostate basal cell differen-
tiation (Additional file 2: Figure S1a).
Genome-wide ChIP-chip data of EP156T and EPT1 cells
have suggested epigenetically repressed patterns of DNA
and histone lysine methylations in the promoter regions of
the AR and classical AR target genes [12] (and results not
shown). We therefore wanted to investigate if the restric-
tion of AR transcription in basal epithelial cells is on an epi-
genetic level that can be reversed by using compounds that
modify epigenetic markers. For this purpose we treated
EP156T and PrEC cells with a combination of the demethy-
lating agent 5-Aza-2′-deoxycytidine (5-Aza-dC) and the
histone deacetylase inhibitor trichostatin A (TSA). We
found that even if imprinted genes were robustly activated
as assessed by RT-qPCR (Additional file 2: Figure S1b), AR
was only marginally altered after 5 day treatment with 5-
Aza-dC and addition of TSA at day 4 and 5 (Additional file
2: Figure S1b) and no androgen-dependent transcription of
the classical AR target genes was detected.
Epithelial to mesenchymal transition was associated with
detectable increase of AR expression in EP156T cells
When epithelial EP156T cells were selected in confluent
monolayers for several months they gave rise to mesen-
chymal type EPT1 cells following EMT [13]. From the
EPT1 cells a succession of mesenchymal type cells with
accumulating malignant features were selected using dif-
ferent growth conditions (Fig. 2a) [15]. The genome-wide
gene expression, epigenetic and functional changes of
EP156T cells and the progeny mesenchymal type EPT1,
EPT2 and EPT3 cells have been previously published
using Agilent microarrays [11–13, 15]. This stepwise
carcinogenic model was utilized to compare AR and AR
target gene expression in epithelial and mesenchymal phe-
notypes with a common genotype. As shown in Fig. 2b,
AR mRNA became detectable in EPT1 cells and remained
at similar levels in the tumorigenic EPT3-PT1 and EPT3-
M1 cells according to both Agilent microarray [15], and
TaqMan RT-qPCR assays. The addition of 10 nM R1881
to the growth medium for 48 hours did not lead to any
significant gene expression changes of either the AR or its
classical targets. This was validated for the AR and the
NKX3-1 and TMPRSS2 genes in all the mesenchymal type
cells using TaqMan RT-qPCR (Fig. 2b/c/d). The EPT3-M1
cells which were derived from a metastasis of the orthoto-
pic mouse tumor EPT3-PT1 were analyzed using RNA-
seq technology (Table 1), revealing that neither the AR
nor its classical target gene expression were affected by 10
nM R1881 for 48 hours. KLK3 was not detectable in any
of the mesenchymal type cells (Table 1 and results not
shown). Even though NKX3-1 and FKBP5 mRNAs were
detectable, their transcription levels were unaffected by
the addition of androgen (Table 1). The endogenous
Table 1 RNA-seq quantification of transcripts in cell lines with or without the androgen agonist R1881
GENES R1881 R1881 R1881 R1881 R1881
EP156T EP156T EPT3-M1 EPT3-M1 LNCaP LNCaP 22Rv1 22Rv1 VCaP VCaP
AR 0 0 3 3 64 36 31 26 125 44
KLK3 0 0 0 0 35 799 4 9 5 52
TMPRSS2 4 4 0 0 18 305 4 6 10 63
NKX3-1 0 0 4 4 40 139 34 40 171 319
KLK2 0 0 0 0 5 169 5 12 447 1010
FKBP5 15 13 40 39 5 331 30 254 7 181
TP63 45 40 0 0 0 0 0 0 0 0
MYC 37 35 21 20 34 8 38 37 91 19
EP156T, EPT3-M1 and LNCaP cells were treated with 10 nM R1881 for 48 hours and 22Rv1 and VCaP cells with 1 nM R1881 for 24 hours. Values are in fragments
per kilobase of exon per million reads mapped (fpkm) and rounded to the nearest integer
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expression of AR protein was detectable using indirect im-
munofluorescence (IF) assays with an anti-AR specific
antibody as exemplified for EPT3-PT1 cells in Fig. 4b. The
latter assay additionally showed that the endogenous AR
was functional regarding cytoplasmic localization in an-
drogen depleted conditions followed by nucleoplasmic ac-
cumulation when 1 nM R1881 was added to the growth
medium. This low-level AR expression was, however, un-
able to direct androgen-dependent classical target gene
expression in this mesenchymal context.
Exogenous expression of the androgen receptor in
EP156T and EPT3-PT1 cells
The initial series of experiments using a variety of growth
factors, growth conditions and combinations revealed the
robust restriction of AR expression in epithelial EP156T
cells and the lack of androgen-dependent gene expression
in PrECs. Even though the AR became detectable following
EMT of EP156T cells, no androgen-dependent induction of
AR target genes could be detected in the mesenchymal type
cells. For this reason we constructed AR expression vectors
in order to examine the hypotheses that AR expression
above a threshold level would be required in order to acti-
vate the classical AR target genes in either the epithelial or
the mesenchymal context.
The lentiviral AR expression vector used in this study
is shown schematically in Fig. 3a. Both the epithelial type
EP156T and mesenchymal type EPT3 prostate cells were
transduced to generate EP156T-AR and EPT3-PT1-AR
cells, respectively. AR mRNA levels were comparable to
expression levels of the androgen responsive LNCaP cell
line according to TaqMan RT-qPCR assays (Fig. 3b).
Western blots showed that AR expression levels of
transduced EP156T-AR and EPT3-PT1-AR cells were
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Fig. 2 AR is expressed in a mesenchymal context, but target genes are repressed. a An experimental model of stepwise transformation of
prostate cells to malignant cells. The model was started from benign EP156T epithelial cells obtained during surgery. The cells were grown to confluence
and kept for almost 4 months without splitting to select for cells with reduced cell-to-cell contact inhibition. EPT1 cells appeared following EMT of EP156T
cells. EPT1 cells were grown to confluence for several weeks and foci appeared in the monolayers. EPT2 cells were picked from the foci and selected and
cloned by growth in soft agar. Neither EP156T nor EPT1 were able to grow in soft agar. Individual clones of EPT2 were next grown in protein free
medium, and the selected cells were tumorigenic and generated EPT3 cells which were recovered from subcutaneous mice tumors and transduced
with a GFP-luciferase vector [15].*Orthotopic injection of EPT3-GFP-luc cells in mice resulted in the EPT3-PT1 cells derived from the primary tumor.
EPT3-M1 cells were isolated from abdominal metastasis. The accumulation of malignant features as one cell type was derived from its progenitor is
listed. RT-qPCR of b AR, c NKX3-1 and d TMPRSS2 expression in epithelial (EP156T) and derived mesenchymal cells compared to LNCaP, treated with 10
nM R1881. Error bars show 95 % confidence intervals. N.D. = not detected. RQ = relative quantity
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Functionality and androgen responsiveness of exogenous
AR in the E and M contexts
In order to test the functionality of the exogenous AR
protein, we first examined both EP156T-AR and EPT3-
PT1-AR cells using indirect immunofluorescense of sin-
gle cells with an anti-AR antibody. Figure 4a shows that
the exogenous AR protein of EP156T-AR cells was local-
ized mostly in the cytoplasm, but also in the nucleo-
plasm in androgen depleted medium. The established
knowledge is that in the absence of androgen ligand the
wild type AR is trapped in a cytoplasmic complex with
HSP90 and other proteins. Upon androgen binding, the
AR undergoes a conformational change and is released
from the cytoplasmic complex, dimerizes and is imported
into the nucleus [28]. Consistent with this, Fig. 4a shows
that in EP156T-AR cells the addition of 1 nM R1881 to
the medium is followed by a complete shift of AR into the
nucleoplasm after 48 hours. In mock transduced EP156T-
LacZ cells no AR was detectable either in the presence or
in the absence of androgen (Fig. 4a). In the epithelial (E)
context the androgen-dependent nuclear import of
exogenous AR was therefore demonstrated. As can be
seen in Fig. 4b, the endogenous AR is weakly detectable in
the cytoplasm of the M type EPT3-PT1-AR cells and nu-
clear import is demonstrated following inclusion of 1 nM
R1881 for 48 hours. Consistent with the Western blot
quantitative results (Fig. 3c) a much stronger AR signal
was found in the cytoplasm of EPT3-PT1-AR cells.
Addition of 1 nM R1881 in the medium induced a
complete shift to the nucleoplasm of both endogenous
and exogenous AR after 48 hours (Fig. 4b).
Exogenous AR directs functional PSA production in E, but
not in M contexts
In order to test for functional PSA production monolayer
cultures of epithelial EP156T-AR and mesenchymal
EPT3-PT1-AR cells were grown with or without andro-
gen. As shown in Fig. 4c, the androgen-dependent PSA
concentration in the supernatant of EP156T-AR cells was
detectable after 3 days following addition of androgen to
sub-confluent monolayers of EP156T-AR cells. Increasing
PSA production from the confluent monolayers was
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Fig. 3 Exogenous expression of the Androgen Receptor. a The human androgen receptor (AR) is mapped to the proximal long arm of the X-chromosome
(Xq11-12). The eight exons that encode the human AR protein are separated by introns of various lengths. Like other nuclear receptors,
the AR protein consists of several functional domains such as the N-Terminal Domain (NTD), DNA-Binding Domain (DBD), the hinge region and the
Ligand-Binding Domain (LBD). The pLENTI6.3/AR-GC-E2325 vector contains the human cytomegalovirus (CMV) immediate early promoter that allows
for high-level, constitutive expression of the AR gene. The figure is adapted from [75]. b RT-qPCR and c Western Blot of AR in cells transduced with the
AR in cultures ± 1 nM R1881 for 48 hours. Error bars show 95 % confidence intervals. RQ = relative quantity. N.D. = not detected
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recorded in the following two weeks. In contrast, no PSA
secretion was detected in EPT3-PT1-AR or control cells
in the presence of androgen (Fig. 4d). The M type cultures
were monitored for up to 14 days without evidence of
PSA secretion.
EP156T and EP156T-AR cells form spheroids in Matrigel,
but only EP156T-AR cells secrete detectable PSA
As exemplified in Fig. 5a, PrEC, EP156T and EP156T-
AR cells formed glandular like spheroids in Matrigel
while M type EPT cells did not exhibit this functional
ability (results not shown). It was noted that EP156T-AR
spheres were consistently smaller than spheres formed
by EP156T and PrEC cells fitting with a proliferation
suppressive effect of androgen-stimulated AR in basal
epithelial cells (Fig. 5a). Similar to in monolayer cultures
EP156T-AR cells were found to secrete PSA in an
androgen-dependent way in Matrigel, but the amounts
detected from the supernatants from the three-
dimensional culture far exceeded that in monolayer
(Fig. 4c). No PSA was detected using the highly sensitive
PSA immunoassay to examine culture supernatant of
EP156T cells in Matrigel. LNCaP cells secreted high
amounts of PSA when grown in Matrigel (Additional file 1:
Table S1). Total RNA was purified from androgen-
stimulated cultures of both EP156T cells and PrEC cells. In
PrEC the AR mRNA was detected in low amounts using
real-time RT-qPCR, but KLK3 mRNA was not detectable
even with androgen available in the growth medium
(results not shown).
The androgen-dependent transcriptome of exogenous AR
in two- and three-dimensional culture
In order to obtain a genome-wide perspective on
androgen-dependent AR target genes in EP156T-AR cells,
total RNA of cells that were grown either with or without
androgen in monolayer cultures or grown in the presence
of androgen in Matrigel cultures for 14 days were profiled
using the Agilent 44 k microarrays. In monolayer culture
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Fig. 4 Exogenous Androgen Receptor is functional. a Exogenous AR in EP156T and b EPT3 translocates to the nucleus upon stimulation with 1
nM R1881. c PSA production in EP156T cells with exogenous AR in monolayer and matrigel-overlay method in regular medium containing 10 nM
testosterone or androgen-free medium. d PSA production in EPT3-PT1-AR and -LacZ stimulated with 1nM R1881. Scale bars 20 μm. Error bars
show ± 95 % confidence interval
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least 2 and a FDR < 10 in cells expressing exogenous AR,
924 genes were upregulated by androgens and 912 down-
regulated. In Matrigel culture 1673 genes were differen-
tially regulated, 894 genes were upregulated by androgen
and 779 downregulated. 855 genes were differentially
expressed following androgen addition both in 2D- and
3D-culture.
As exemplified in Fig. 5, several categories of genes
switched expression patterns in EP156T-AR cells in an
androgen-dependent way, including classical AR target
genes (Fig. 5b) and prostate characteristic integrins and
laminins (Fig. 5c). Interestingly, the patterns of change
of these genes were similar for androgen-induced
EP156T-AR cells both in monolayer cultures and in
Matrigel cultures. These transcription levels were also
validated using RT-qPCR for AR, KLK3, TP63 and
TMPRSS2 (Fig. 5d-g).
One advantage of the gene expression analysis is that
the AR probe on the Agilent G4845 array targets the 3’-
UTR (untranslated region) of the AR mRNA. This se-
quence is absent in the AR mRNA that is transcribed
from the AR open reading frame of the expression vec-
tor. When the TaqMan real-time RT-qPCR assay is used
to detect AR exon sequences in parallel, a distinction
can be made between endogenous and exogenous AR
mRNAs of the same cell cultures. It was of considerable
interest to examine the possibility if basal AR expression
might have a positive feedback effect on endogenous AR
transcription. Expression levels of AR in the absence and
presence of androgen were examined in cells with or
without exogenous AR expression, but endogenous AR
was not detectable. These experiments showed that in
EP156T-AR cells the restriction of endogenous AR ex-
pression persisted even if the classical AR target genes
were activated by exogenous AR and androgen.
Discussion
AR negative (AR−) prostate epithelial stem cells divide
asymmetrically to self-renew and to differentiate into either
non-proliferating AR− neuroendocrine cells or TP63+/AR−
transient amplifying (TA) cells in the normal adult prostate.
The basally located AR− TA cells undergo a limited number
of amplifying rounds of proliferation before maturing into
TP63+/PSCA+ intermediate cells [7, 29–31]. When AR ex-
pression is induced by incompletely understood mecha-




































































































Fig. 5 Forced Androgen Receptor expression induces target gene expression. a Phase-contrast of cells grown in Matrigel-overlay culture at day
12 with 10 nM testosterone. b-c Agilent microarray gene expression data were analyzed using SAM in the J-Express software to find fold change
upregulation (positive numbers) or downregulation (negative numbers) of the shown genes in EP156T-AR cells stimulated by 10 nM Testosterone
for 14 days compared to EP156T-AR cells grown in androgen free medium. d-g RT-qPCR of EP156T-AR cells in androgen free or medium with 10
nM testosterone in 2D or Matrigel-overlay culture. d AR, e KLK3/ACTB ratio, f TP63 and g TMPRSS2. Error bars show 95 % confidence intervals. RQ =
relative quantity. Scale bars 200 μm. N.D. = not detected
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cells terminally differentiate into luminal-secretory cells. An
important aspect of the terminal differentiation is that
androgen-bound AR represses MYC to inhibit proliferation
and activates a large number of luminal secretory target
genes [7, 9].
Many groups have investigated in vitro the molecular
events associated with replication and differentiation of
prostate basal cells to luminal secretory cells and found
restricted AR and AR target gene expressions [26, 32–38].
One study has reported that co-treatment of prostate
basal cells with clorgyline, 1,25-dihydroxyvitamin D3, all-
trans retinoic acid and TGF-β1, induced expression of AR
and loss of the basal marker KRT14 [39]. Lamb et al.
found that confluent monolayers of primary prostate basal
cells treated with dihydrotestosterone and FGF7 for 2–3
weeks differentiated into a top layer of luminal cells with
expression of AR and classical AR target genes together
with additional markers of terminally differentiated lu-
minal secretory cells [21]. They found, however, that once
cells reached passage 5, the efficiency of luminal differenti-
ation was dramatically reduced. On only one occasion
were they able to induce luminal differentiation in a
patient-derived immortalized basal cell line. This is con-
sistent with our results with the hTERT immortalized
EP156T cells and the failure to demonstrate AR and clas-
sical AR target gene expression using either the conditions
described by Lamb et al. or additional conditions includ-
ing long-term confluent cultures, 3D Matrigel cultures,
co-cultures with mesenchymal type cells and different
combinations of biologically active compounds.
A few studies have reported morphological features of
prostate basal cell differentiation using different treat-
ments, such as the cell monolayer becoming stratified or
forming gland like buds [40], but with either lack of AR
expression or persistent expression of basal cell markers
[35, 40–42]. Of interest, the original publication on the
establishment of the EP156T cell line found that it
formed glandular like structures in Matrigel and with in-
direct immunofluorescence detection of AR and KLK3
[20]. The EP156T cells, received at passage 37 in our la-
boratory and with a carefully kept passage history, still
form glandular like structures in Matrigel, but using
both highly sensitive real-time RT-qPCR assays and PSA
detection assays we have been unable to detect AR and
KLK3 production by these cultures. Additionally, treat-
ment with the epigenetic modifying drugs 5-Aza-dC and
TSA was not able to induce AR transcription, indicating
that restriction of AR expression is not predominantly
epigenetic but rather may be due to lack of cofactors.
In order to examine further the nature of the restric-
tion of AR and AR target gene expression in EP156T
cells, EP156T-AR cells stably expressing exogenous AR
were selected. These cells were passaged in androgen de-
pleted medium due to the potential of exogenous AR to
induce terminal differentiation and growth arrest [7].
When androgen was added to EP156T-AR cells, both
monolayer cultures and Matrigel cultures produced KLK3
mRNA and protein. Several previous in vitro differenti-
ation studies of prostate basal epithelial cells have noted a
late restriction where AR and KLK3 mRNAs can be de-
tected without the corresponding proteins [37, 43–45].
The PSA assay verified that EP156T-AR cells secreted
PSA to the supernatant in an androgen-dependent way.
There was therefore no evidence of restricted translation
in this model.
According to genome-wide microarray analyses, the
addition of androgen to EP156T-AR cells induced the
classical AR target genes both in monolayer and Matri-
gel cultures. This was in contrast to androgen treated
EP156T cells or in EP156T-AR cells with androgen de-
pleted medium. The endogenous AR mRNA remained
repressed, however, both in monolayer cultures and in
Matrigel. The possibility that androgen-bound AR could
have a positive feedback effect on endogenous AR tran-
scription was therefore not supported by the present
studies. It remains a high priority future task to identify
the precise molecular mechanisms of endogenous AR
transcription activation in prostate basal epithelial cells.
Possibilities include lack of essential cofactors, epigenetic
repression or selection of mutants.
Downregulation of basal cell integrins α6β4 and α3β1
is considered a critical event in luminal differentiation
[21], but it is unclear whether AR represses integrin
mRNA transcription or whether loss of integrin expres-
sion must precede AR expression [30]. Interestingly, an-
drogen addition to EP156T-AR cells was followed by
downregulation of ITGA3, ITGA4 and ITGA6. LAMC2
was downregulated in an androgen-dependent way in
EP156T-AR cells. LAMC2 is the laminin that binds
integrins α6β4 and α3β1 in basal prostate cells. Several
additional integrins and laminins changed their expres-
sion in androgen treated EP156T-AR cells, indicating
that the AR is involved in co-ordinated changes of integ-
rins and laminins in differentiating prostate basal cells.
The lineage hierarchy of prostate epithelial differenti-
ation remains inadequately defined [46]. The origin and
relationship between the benign prostate cells that initi-
ate cancer and the cancer stem-like cells that propagate
tumors are still vigorously investigated [10, 47, 48]. Re-
cent reports suggest that luminal epithelial stem cells
can act as the cell of origin of prostate cancer in the
form of a castration-resistant Nkx3-1-expressing cell
(CARN) [49]. Additionally both mouse and human epi-
thelial luminal cells can establish prostate organoids in
vitro [50, 51].
AR is central to growth and survival of both benign
and malignant prostate epithelial cells, but the mecha-
nisms seem to be very different in normal prostate
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homeostasis and cancer growth. In normal prostate epi-
thelial cells the requirement for androgen is mediated
through AR in the prostate stromal cells. Stromal
androgen-bound AR induces secreted growth factors, so-
called andromedins such as IGF-1, EGF, FGF7 and FGF10,
to promote growth and survival of the epithelium [6].
During prostate carcinogenesis AR expression in the
stroma decreases concurrently with increased AR expres-
sion in the tumor cells as prostate cancer progresses [52],
and stromal cells surrounding metastatic prostate cells are
AR negative, suggesting that cancer cells themselves start
to supply the necessary andromedins, releasing themselves
from the requirement of AR-positive stromal cells and an-
drogens. Prostate carcinogenesis and progression there-
fore seem to involve acquisition of autocrine growth
signals in addition to a switch of the AR from being a cell
intrinsic inhibitor of proliferation to becoming a stimula-
tor of proliferation [6, 8, 52].
The AR is critical for proliferation and survival of the
bulk population of prostate cancer cells both at early
stages and during CRPC as reflected by the effect of AR-
inhibiting therapy [53–55]. But prostate cancer always es-
capes from these treatments in support of the hypothesis
that a small sub-population of AR− and androgen-
independent prostate CSCs is the source of more differen-
tiated AR+ bulk population of prostate cancer cells [56].
The hypothesis that ADT may lead to a “rebound” in-
crease in the number of AR− cells with basal cell and CSC
features, is reviewed elsewhere (see [3] and references
therein [57–61]). Additional studies have reported
androgen-independent early human prostate adenocarcin-
oma cells and prostate CSCs with low AR [48, 62–67].
The existence of AR− prostate CSC with basal cell fea-
tures could help to explain the recurrence of transdiffer-
entiated neuroendocrine cancers following highly
potent ATT of CRPC [68, 69]. It is not clear, however, if
either loss of negative feedback by differentiated pros-
tate cancer cells on CSC proliferation or if therapeutic
inhibition of the AR could contribute to increase the
pool of prostate CSCs [3, 70, 71] or contribute to induc-
tion of EMT, epithelial mesenchymal plasticity and in-
creased aggressiveness and reprogramming potential in
prostate CSCs [5, 69, 72–74]. In this regard, it is note-
worthy that mesenchymal type EPT3-AR cells, in con-
trast to epithelial type EP156T-AR cells, were androgen
non-responsive. They were unable to produce detect-
able PSA in the culture supernatants even with higher
levels of exogenous AR protein than in EP156T-AR and
LNCaP cells for up to 2 weeks in androgen containing
growth medium. The restricted PSA expression in the
mesenchymal context suggests that if ADT increases
the pool of mesenchymal type prostate cancer cells,
then this might go undetected during PSA monitoring
of disease progression.
Conclusions
Androgen receptor expression and classical target gene
expression were restricted and androgen non-responsive
in PrECs and immortalized EP156T cells both in mono-
layer and Matrigel cultures. Expression of exogenous AR
in EP156T-AR cells induced an extensive androgen-
dependent trancriptome including classical target genes.
No restriction of KLK3 mRNA translation was observed
and PSA was detected in confluent monolayers and in
Matrigel cultures. However exogenous AR with or with-
out androgen did not induce endogenous AR mRNA
transcription. Low-level AR and high-level exogenous
AR were unable to induce KLK3 mRNA or other clas-
sical AR target genes in mesenchymal type prostate cells.
In summary these results demonstrate the context
dependent function of the AR, and that epigenetics and/
or availability of cofactors greatly influence the AR tran-
scriptome and ultimately if AR acts in a tumor suppres-
sive or oncogenic manner. It also demonstrates that PSA
might not be a good biomarker in cancers with high cel-
lular plasticity, particularly for cancers that are induced
towards a mesenchymal phenotype. However more
knowledge is required to understand the specific condi-
tions that govern AR-regulated phenotypes including its
role in differentiation.
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Additional file 1: Table S1. Supernatant PSA assay. Various cell lines
were stimulated with different combinations of growth factors and in several
co-cultures. Represented here is a selection of these samples. Concentrations:
R1881 (10 nm), FGF7 (10 ng/ml), PD98059 MAPKK inhibitor (30 mM), EGF
(5 ng/ml) and co-culture with 50-75 % EPT1B8 cells. + denotes added growth
factor. Mesenchymal EPT1 cells with p63KD (p63 knockdown), CDH1 or
ΔNp63α are described in [14]. (XLS 46 kb)
Additional file 2: Figure S1. Differentation in high calcium medium or
using epigenetically modifying methods. a RT-qPCR of AR and TP63 in PrEC
cells after 6 days culture under differing calcium and FCS concentrations. b RT-
qPCR of XIST, AR and TP63 in EP156T and PrEC cells treated with 5’-Aza-dC for
5 days and TSA day 4 and 5. N.D. = not detected. Error bars show 95 % confi-
dence intervals. RQ = relative quantity. (PDF 54 kb)
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